Voyager Therapeutics Earns Buy Rating Due to Promising Alzheimer's Gene Therapy and Significant Share Price Potential

Voyager Therapeutics has a Buy rating from Citi's Samantha Semenkow due to promising results in its Alzheimer's disease program. The company's novel APOE-targeted gene therapy using the TRACER capsid platform has shown positive outcomes in preclinical studies. Voyager's pipeline also includes other innovative therapies, and the expected share price return of 257.1% supports the optimistic outlook on the stock. Semenkow is an analyst with an average return of -15.1% and a 29.41% success rate.

Voyager Therapeutics, Inc. (Nasdaq: VYGR) has received a Buy rating from Citi analyst Samantha Semenkow, driven by the company's promising results in its Alzheimer's disease (AD) program. The analyst's optimistic outlook is supported by the expected share price return of 257.1%, reflecting the potential of Voyager's innovative therapies. Semenkow's average return of -15.1% and a 29.41% success rate further bolster her credibility [1].

Voyager's latest advancement in AD treatment involves a novel APOE-targeted gene therapy using the TRACER capsid platform. Preclinical studies have shown positive outcomes, with a single intravenous (IV) injection of a TRACER capsid carrying a bifunctional vector significantly reducing endogenous APOE4 in key AD-relevant brain regions of APOE4 knock-in mice. This therapy aims to decrease expression of the APOE4 variant, which is strongly linked to a higher risk of developing AD, while delivering the APOE2 variant, associated with a lower risk [2].

Voyager's AD pipeline now includes four wholly-owned assets: VY7523, a pathologic-specific anti-tau antibody; VY1706, an IV-delivered tau silencing gene therapy; a vectorized anti-Aβ antibody gene therapy; and the new APOE gene therapy program. These programs target tau, amyloid, and APOE, which are believed to be the three most-promising targets in AD treatment [2].

Voyager anticipates presenting early data on the APOE program at an upcoming scientific meeting in 2025, further validating its potential. The company's TRACER capsid discovery platform has enabled rapid discovery of novel AAV capsids, facilitating gene therapy delivery across the central nervous system (CNS) [2].

Voyager's progress in AD treatment aligns with the company's broader mission to leverage genetics to treat neurological diseases. The company's pipeline includes programs for AD, Friedreich's ataxia, Parkinson's disease, ALS, and multiple other CNS diseases [2].

References:
[1] https://www.biospace.com/press-releases/voyager-adds-fourth-wholly-owned-alzheimers-disease-program-to-pipeline-complementing-existing-tau-and-amyloid-assets-with-new-apoe-approach
[2] https://www.voyagertherapeutics.com